ArticleCancer immunology, immunotherapy : CII2021

ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer.

Jiexia Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.